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The fact that several different human virus oncoproteins,
including adenovirus type 9 E4-ORF1, evolved to target the
Dlg1 mammalian homolog of the membrane-associated
Drosophila discs-large tumor suppressor has implicated
this cellular factor in human cancer. Despite a general
belief that such interactions function solely to inactivate
this suspected human tumor suppressor protein, we
demonstrate here that E4-ORF1 specifically requires
endogenous Dlg1 to provoke oncogenic activation of
phosphatidylinositol 3-kinase (PI3K) in cells. Based on
our results, we propose a model wherein E4-ORF1 binding
to Dlg1 triggers the resulting complex to translocate to the
plasma membrane and, at this site, to promote Ras-
mediated PI3K activation. These findings establish the
first known function for Dlg1 in virus-mediated cellular
transformation and also surprisingly expose a previously
unrecognized oncogenic activity encoded by this sus-
pected cellular tumor suppressor gene.
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Introduction
Dlg1, also known as hDlg or SAP97, is a mammalian homolog
of the Drosophila discs-large (Dlg) tumor suppressor protein
(Lue et al, 1994; Muller et al, 1995). These proteins localize
to specialized cell–cell contact membrane sites (i.e., septate,
adherens, and synaptic junctions) and are required for both
junction formation and proper polarity establishment in cells
(Humbert et al, 2003; Nguyen et al, 2003; Laprise et al, 2004).
As MAGUK family proteins, they lack catalytic activity and
instead consist of multiple protein interaction modules, inclu-
ding three PDZ domains, an SH3 domain, and a guanylate
kinase-homology (GK) domain (Gonzalez-Mariscal et al,
2000). Accordingly, these polypeptides function as molecular
scaffolds to organize their targets into supramolecular signal-
ing complexes and to translocate them to the plasma mem-
brane (Kim and Sheng, 2004).
Evidence supports the assertion that Drosophila Dlg and
mammalian Dlg1 encode evolutionarily conserved tumor
suppressor proteins. Drosophila Dlg mutations cause cellular
overgrowth in the larval brain and imaginal discs, where cells
exhibit a neoplastic morphology (Woods et al, 1996). Upon
transplantation into wild-type (wt) flies, Dlg-mutant imaginal
discs produce cancerous outgrowths resembling metastatic
tumors (Woodhouse et al, 1998), perhaps reflecting the
capacity of Dlg to prevent abnormal cellular invasion into
adjacent tissues (Goode and Perrimon, 1997). Furthermore,
transgenic expression of Dlg1 by Drosophila Dlg mutants
rescues their cellular overgrowth phenotype (Thomas et al,
1997), demonstrating conservation of the tumor suppressor
function. Dlg1 likewise prevents unscheduled cellular pro-
liferation in ocular lenses of mice (Nguyen et al, 2003),
sustains mutations accompanied by a loss of heterozygosity
in human breast carcinomas (Fuja et al, 2004), and exhibits
reduced expression in invasive human cervical carcinomas
(Cavatorta et al, 2004; Lin et al, 2004).
Reports showing that three different human virus onco-
proteins independently evolved to target Dlg1 in cells provide
the most compelling evidence implicating this cellular factor
in human cancer. Human adenovirus type 9 (Ad9) elicits
mammary tumors in experimental animals (Javier et al,
1991), and high-risk human papillomavirus (HPV) and
human T-cell leukemia virus type 1 (HTLV-1) are etiological
agents for cervical carcinoma and adult T-cell leukemia,
respectively (Barmak et al, 2003; Heise, 2003). Strikingly,
the otherwise unrelated oncogenic determinants of these
tumor viruses (Ad9 E4-ORF1, HPV E6, and HTLV-1 Tax)
similarly possess a carboxyl-terminal PDZ domain-binding
motif (PBM) that mediates binding to several different cellu-
lar PDZ proteins (Lee et al, 1997; Rousset et al, 1998;
Mantovani and Banks, 2001), including Dlg1, which is the
only PDZ-protein target common to all three viral proteins.
Additionally, the PBM plays a key role in cellular transforma-
tion induced by these oncoproteins (Lee et al, 1997; Watson
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et al, 2003; Hirata et al, 2004). Evidence specifically impli-
cating endogenous Dlg1 in this process is currently lacking,
but it has been reasonably hypothesized that the tumorigenic
potentials of these viral proteins stem partly from an ability
to inactivate this suspected tumor suppressor protein.
Consistent with this idea, HPV E6 promotes degradation
of overexpressed Dlg1 (Gardiol et al, 1999) and HTLV-1 Tax
overcomes cell-cycle arrest caused by Dlg1 overexpression
(Suzuki et al, 1999), although one caveat is the uncertain
physiological relevance of these findings.
The oncogenic potential of Ad9 E4-ORF1 was recently
demonstrated to depend on its ability to promote constitutive,
growth factor-independent stimulation of cellular phosphati-
dylinositol 3-kinase (PI3K) (Frese et al, 2003). This critical
activity of E4-ORF1 requires the PBM, which mediates inter-
actions with Dlg1 (Lee et al, 1997) and three other cellular
PDZ proteins (MUPP1, MAGI-1, and ZO-2) (Glaunsinger et al,
2000, 2001; Lee et al, 2000). We report here that specific
binding of E4-ORF1 to endogenous Dlg1 promotes Ras-
mediated PI3K activation in cells, revealing the first estab-
lished function for Dlg1 in viral oncoprotein-mediated cellu-
lar transformation. The additional finding that functional as
opposed to inactivated Dlg1 mediates E4-ORF1-induced PI3K
activation also exposed a surprising oncogenic activity for
this suspected tumor suppressor protein.
Results
Mutation of MUPP1, MAGI-1, or Dlg1 fails to reproduce
PI3K activation induced by E4-ORF1
Given that Dlg1 as well as ZO-2 (Chlenski et al, 1999a, b,
2000) are suspected tumor suppressors and that E4-ORF1
sequesters MUPP1, MAGI-1, and ZO-2 in the cytoplasm
of cells (Glaunsinger et al, 2000, 2001; Lee et al, 2000), we
postulated that PI3K activation provoked by Ad9 E4-ORF1
may stem from inactivation of one of these cellular targets.
If so, disruption of the corresponding cellular gene should
recapitulate E4-ORF1-induced PI3K activation in cells.
To explore this idea, we isolated mouse embryo fibroblasts
(MEF) from wt mice and matched littermates carrying either a
large deletion mutation encompassing the entire MUPP1 gene
(Bell et al, 1995) or a targeted mutation interrupting either
the MAGI-1 gene (in preparation) or the Dlg1 gene (Caruana
and Bernstein, 2001). The lack of ZO-2 mutant mice pre-
cluded inclusion of the respective mutant MEF in this study;
however, ZO-2 seems unlikely to play a role in E4-ORF1-
induced PI3K activation given that E4-ORF1 proteins encoded
by human Ad3, Ad5, and Ad12 activate PI3K (Frese et al,
2003), yet do not bind this single, unique PDZ-protein target
of Ad9 E4-ORF1 (Glaunsinger et al, 2001).
MUPP1/ or MAGI-1/ MEF failed to express the respec-
tive wt gene product, as did Dlg1gt/gt MEF, which instead
expressed the Dlg/b-geo fusion protein containing the amino-
terminal 549 residues of the B900-residue wt Dlg1 poly-
peptide (Supplementary Figure 1A and B). Following serum
deprivation and subsequent stimulation by platelet-derived
growth factor (PDGF), all mutant MEF and matched wt
MEF displayed comparable basal and PDGF-induced levels
of activated, phosphorylated protein kinase B (PKB) (Supple-
mentary Figure 1A), a key downstream effector of PI3K.
Throughout this study, Thr308- and Ser473-phosphospecific
PKB antibodies yielded identical results, so each was used
interchangeably. As Dlg/b-geo could feasibly retain some
function, including the postulated capacity to suppress PI3K
activation, we stably downregulated this protein in Dlg1gt/gt
MEF using a Dlg1-specific short hairpin RNA (shRNA).
Despite substantial, specific downregulation of Dlg/b-geo,
Dlg1 shRNA-expressing Dlg1gt/gt MEF displayed basal and
PDGF-induced levels of activated PKB identical to those of
Dlg1gt/gt MEF (Supplementary Figure 1C). These observations
did not support our hypothesis that E4-ORF1-induced PI3K
activation simply results from functional inactivation of
MUPP1, MAGI-1, or Dlg1 in cells.
PI3K activation and anchorage-independent growth
induced by E4-ORF1 depend on Dlg1
Our negative results prompted consideration of the opposite
hypothesis, wherein PI3K activation induced by E4-ORF1
requires one of its cellular PDZ-protein targets. This model
predicted instead that MUPP1/, MAGI-1/, or Dlg1gt/gt
MEF might fail to support E4-ORF1-induced PKB activation.
Significantly, during transient E4-ORF1 expression, Dlg1gt/gt
MEF, but not MUPP1/ or MAGI-1/ MEF, displayed a
substantial defect in supporting this activity compared to
matched wt or heterozygous mutant MEF (Figure 1A).
Though prolonged exposures revealed that Dlg1gt/gt MEF
retained a weak capacity to support E4-ORF1-induced
PKB activation, this remnant activity was eliminated by
Dlg1 shRNA expression (Figure 1B). Additionally, whereas
Dlg1þ /þ MEF stably expressing E4-ORF1 showed constitu-
tive activation of endogenous PKB and grew in soft agar,
Dlg1gt/gt MEF stably expressing E4-ORF1 lacked these pheno-
types (Figure 2A and B), similar to the former MEF treated
with the PI3K inhibitor drug LY294002 (LY) (Figure 2C
and D). Also notable was that Dlggt/gt MEF and Dlggt/gt MEF
expressing the Dlg1 shRNA failed to grow in soft agar
(Figure 2B). These findings demonstrated a requirement for
functional rather than inactivated Dlg1 in both PI3K acti-
vation and oncogenic transformation induced by E4-ORF1
in MEF.
I3-containing Dlg1 isoforms support E4-ORF1-induced
PI3K activation
Due to several short insertion elements (e.g., I1, I2, I3) that
arise by alternative splicing (see Supplementary Figure 1B),
multiple Dlg1 isoforms can be produced in cells (Lue et al,
1994; McLaughlin et al, 2002). Despite comparable binding
of E4-ORF1 to the Dlg1-I2, -I3, -I1I2, and -I1I3 isoforms
(Figure 3A), transient expression of green fluorescent protein
(GFP)-tagged Dlg1-I3, but not GFP-Dlg1-I2, restored robust
E4-ORF1-induced PKB activation in Dlg1 shRNA-expressing
Dlg1gt/gt MEF (Figure 3B). A nucleotide mismatch between
the mouse Dlg1 shRNA and the rat Dlg1 cDNA used to
construct Dlg1 plasmids permitted GFP-Dlg1 expression in
these cells.
In Dlg1gt/gt MEF, E4-ORF1-induced PKB activation in-
creased markedly even at low undetectable levels of HA
epitope-tagged (HA)-Dlg1-I3 expression, peaked at moderate
levels, and did not increase appreciably at higher levels
(Figure 3C). By contrast, GFP-tagged Dlg1-I2, MUPP1,
MAGI-1, ZO-2, or Dlg1-related SAP102 (Thomas et al, 1997)
lacked any such activity (Figure 3D). GFP-Dlg1-I3 likewise
enhanced PKB activation induced by related human Ad3 and
Ad5 E4-ORF1 proteins (Frese et al, 2003) (Figure 3E), but not
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by cellular H-RasV12 or polyomavirus middle T (PyMT)
(Figure 3F). Additionally, Dlg1-I1I2 and Dlg1-I1I3 mirrored
Dlg1-I2 and Dlg1-I3, respectively, in their capacities to sup-
port E4-ORF1-induced PKB activation (e.g., see Figure 4B)
(data not shown). Thus, wt Dlg1 mediates E4-ORF1-induced
PI3K activation in cells, and I3-containing Dlg1 isoforms
mainly provide this function. The lack of an I3 element in
Dlg/b-geo explains, at least in part, its defect in supporting
E4-ORF1-induced PI3K activation.
Multiple Dlg1 domains contribute to E4-ORF1-induced
PI3K activation
We next examined the capacity of GFP-Dlg1-I3 deletion
mutants (Figure 4A; group 1) to rescue E4-ORF1-induced
PI3K activation in Dlg1gt/gt MEF. Like wt Dlg1-I3, Dlg1-I3
mutants missing the amino-terminal region (NT), PDZ3,
SH3, or GK restored robust E4-ORF1-induced PKB activation
(Figure 4B). The modest defect of Dlg1-I3DGK probably arises
indirectly from its unique, partial nuclear accumulation
(Kohu et al, 2002) (data not shown). By contrast, Dlg1-I3
mutants missing PDZ1 or PDZ2 exhibited modest or severe
activity loss, respectively, whereas Dlg1-I3 mutants missing
either all three PDZ domains or PDZ1þ 2, which forms a
single conformational unit (Lue et al, 1996), lacked any acti-
vity (Figure 4B). Given that PDZ1þ 2 was both necessary and
sufficient to mediate Dlg1 binding to E4-ORF1 (Figure 4C),
the defects of the latter Dlg1 mutants likely reflect nearly
complete or complete disruption of this interaction.
To assess possible roles for other Dlg1 domains in E4-
ORF1-induced PI3K activation, we examined additional Dlg1
mutants that retain PDZ1þ 2 and I3, but lack certain other
elements (Figure 4A; group 2). We excluded mutants with the
DGK mutation due to their confounding partial or complete
nuclear localization. Whereas Dlg1 mutants missing either
the unique region between PDZ2 and PDZ3 (U3) or the
SH3 domain restored E4-ORF1-induced PKB activation, Dlg1
mutants lacking both elements did not (Figure 4D), suggest-
ing that U3 and SH3 have redundant functions for this
activity. In summary, Dlg1 requires PDZ1þ 2, I3, and either
U3 or SH3 to support E4-ORF1-induced PI3K activation.
E4-ORF1 causes endogenous Dlg1 to accumulate
at the plasma membrane
E4-ORF1 sequesters endogenous MUPP1, MAGI-1, and ZO-2
aberrantly within detergent-insoluble complexes in the cyto-
plasm of cells, suggesting functional inactivation of these
cellular targets. We postulated that E4-ORF1 differentially
affects Dlg1 in cells because our results implicated functional
rather than inactivated Dlg1 in E4-ORF1-induced PI3K activa-
tion. In rat CREF fibroblasts stably expressing E4-ORF1, endo-
genous ZO-2, but not endogenous Dlg1, was sequestered
within detergent-insoluble complexes (Figure 5A) that appeared
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Figure 1 E4-ORF1-induced PKB activation depends on Dlg1. (A) E4-ORF1-induced PKB activation is deficient in Dlg1gt/gt MEF. Cells on 6-cm
dishes were lipofected with pGW1-HA-PKB (0.5, 1, or 1mg for MUPP1, MAGI-1, or Dlg1 MEF, respectively) and either empty pGW1 () or
pGW1-E4-ORF1 (þ ) (100, 20, or 50 ng for MUPP1, MAGI-1, or Dlg1 MEF, respectively). Cells were serum starved, and equal amounts of cell
extracts were blotted with antibody to (P)Thr308 PKB, (P)Ser473 PKB, HA, MUPP1, MAGI-1, or Dlg1. For this type of experiment, the small
quantity of E4-ORF1 plasmid needed to achieve optimal HA-PKB activation did not yield detectable levels of E4-ORF1 expression. (B) Dlg1
shRNA expression abrogates weak PKB activation induced by E4-ORF1 in Dlg1gt/gt MEF. On 6-cm dishes, Dlg1gt/gt MEF stably transfected with
either empty pSUPER () or pSUPER-Dlg1 shRNA (þ ) were lipofected with pGW1-HA-PKB (0.5 mg) and either empty pGW1 () or pGW1-E4-
ORF1 (10, 20, or 50 ng). Cells were serum starved, and equal amounts of cell extracts were blotted with antibody to (P)Thr308 PKB, HA,
or Dlg1.
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as cytoplasmic punctae in indirect immunofluorescence (IF)
assays (Figure 5B). Close inspection of these IF assays revea-
led that, inB50% of the E4-ORF1-expressing CREF cells, but
in none of the control CREF cells, some Dlg1 accumulated
at the plasma membrane (Figure 5B), the known location
for E4-ORF1-induced PI3K activation (Frese et al, 2003).
Moreover, treatment with chlorpromazine, an inhibitor of
receptor-mediated endocytosis (Sieczkarski and Whittaker,
2002), increased detection of Dlg1 plasma membrane staining
to 95% of E4-ORF1-expressing CREF cells, but to less than
10% of control CREF cells (Figure 5C), implying that E4-
ORF1-induced Dlg1 membrane accumulation is a dynamic
process continually counterbalanced by endocytosis.
Binding to E4-ORF1 triggers Dlg1-I3 to translocate
to the plasma membrane
We also tested whether E4-ORF1 can cause GFP-Dlg1 to
accumulate at the plasma membrane of 293T cells. When
expressed alone, GFP-Dlg1-I2 and GFP-Dlg1-I3 similarly loca-
lized diffusely in the cytoplasm (Figure 5D), as did E4-ORF1,
which additionally exhibited characteristic accumulation
within cytoplasmic punctae (data not shown) (Weiss et al,
1996). Expression of GFP-Dlg1-I3 with E4-ORF1, however,
caused both proteins to translocate to the plasma membrane
in B70% of transfected cells (Figure 5D). By contrast,
expression of GFP-Dlg1-I2 with E4-ORF1 instead promoted
both proteins to concentrate within cytoplasmic punctae in
B70% of transfected cells (Figure 5D). The common require-
ment for I3 in both PI3K activation and Dlg1 membrane
translocation induced by E4-ORF1 served to link these two
processes.
Unpublished data indicate that E4-ORF1 consists of two
separate domains, the PBM and Domain 2 (D2), the latter of
which mediates binding to an undetermined cellular phos-
phoprotein (pp70). Supporting this model, PBM mutations
(e.g., V125A, T123D, and IIIA) eliminate E4-ORF1 binding to
PDZ-protein targets, but not to pp70, and, conversely, D2
mutations (e.g., IA, IIA, and IIB) abolish E4-ORF1 binding
to pp70, but not to PDZ-protein targets (in preparation) (Lee
et al, 1997; Weiss and Javier, 1997). Disruption of either
domain alone, however, suffices to inhibit E4-ORF1-induced
PI3K activation (Frese et al, 2003).
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Figure 2 Dlg1 is also required for E4-ORF1 to induce anchorage-independent growth in MEF. (A) Dlg1gt/gt MEF stably expressing E4-ORF1 fail
to accumulate activated, endogenous PKB. Dlg1þ /þ or Dlg1gt/gt MEF stably transfected with either empty pBABE (vector) or pBABE-E4-ORF1
(E4-ORF1) were serum starved, and equal amounts of cell extracts were blotted with antibody to (P)Thr308 PKB, PKB, or E4-ORF1. (B) Dlg1gt/gt
MEF stably expressing E4-ORF1 fail to grow in soft agar. 105 viable MEF stably transfected with empty pBABE (vector), pBABE-E4-ORF1 (E4-
ORF1), or pSUPER-Dlg1 shRNA (Dlg1 shRNA) were suspended in agar and photographed 21 days later. (C) LY294002 (LY) treatment blocks
endogenous PKB activation in Dlg1þ /þ MEF stably expressing E4-ORF1. Dlg1þ /þ MEF stably transfected with pBABE (vector) or pBABE-E4-
ORF1 (E4-ORF1) were serum starved, and were treated with DMSO vehicle or 10mM LY for 15 min. Equal amounts of cell extracts were
analyzed as described above in A. (D) LY treatment inhibits anchorage-independent growth of Dlg1þ /þ MEF stably expressing E4-ORF1. Soft
agar assays were conducted as described above in (B), except that the culture medium contained DMSO vehicle (LY) or 10 mM LY (þLY).
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We examined whether the two E4-ORF1 domains also
function as a unit to promote GFP-Dlg1-I3 translocation to
the plasma membrane. In these assays with 293 T cells, D2
mutant IIB behaved like wt E4-ORF1, whereas PBM mutant
IIIA lacked any appreciable activity (Figure 5E). Other E4-
ORF1 D2 and PBM mutants exhibited phenotypes indistin-
guishable from those of IIB and IIIA, respectively (data not
shown). Results with PBM mutants reinforced the link bet-
ween E4-ORF1-induced PI3K activation and Dlg1 membrane
translocation, and further suggested that the interaction
per se between E4-ORF1 and Dlg1-I3 suffices to trigger the
latter process. Thus, E4-ORF1 binding to Dlg1 PDZ1þ 2 may
cause cytoplasmic Dlg1 in the inactive, closed conformation
to assume an active, open conformation capable of binding
membrane- and cytoskeleton-associated proteins (Wu et al,
2000). The dispensability of E4-ORF1 D2 for this process
signified specific participation in the subsequent PI3K activa-
tion event.
Identical Dlg1 domains determine both PI3K activation
and Dlg1 membrane translocation induced by E4-ORF1
We next tested the capacity of E4-ORF1 to promote mem-
brane translocation of all Dlg1 proteins shown in Figure 4A.
Identical to wt Dlg1, Dlg1 mutants expressed alone in 293 T
cells localized diffusely in the cytoplasm (e.g., see Figure 5D)
(data not shown). Again, the single exception was Dlg1-
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Figure 3 I3-containing Dlg1 isoforms mediate E4-ORF1-induced PKB activation. (A) E4-ORF1 binds comparably to four Dlg1 isoforms. COS7
cells on 6-cm dishes were lipofected with pGW1-E4-ORF1 (1.5mg) and either empty pGW1 () or the indicated pGW1-HA-Dlg1 isoform plasmid
(1.5 mg). Equal amounts of cell extracts were precipitated with HA antibody. Recovered proteins (left) or cell extracts (right) were blotted with
antibody to HA or E4-ORF1. (B) Dlg1-I3, but not Dlg1-I2, rescues the defect of Dlg1 shRNA-expressing Dlg1gt/gt MEF in supporting E4-ORF1-
induced PKB activation. The latter cells on 6-cm dishes were lipofected with pGW1-HA-PKB (0.5 mg), either empty pGW1 () or pGW1-E4-
ORF1 (þ ) (20 ng), and either empty peGFP () or the indicated peGFP-Dlg1 isoform plasmid (2.5mg). Cells were serum starved, and equal
amounts of cell extracts were blotted with antibody to (P)Thr308 PKB, HA, or GFP. (C) Low, undetectable levels of Dlg1-I3 expression are
sufficient to enhance E4-ORF1-induced PKB activation in Dlg1gt/gt MEF. The latter cells on 6-cm dishes were lipofected with pGW1-HA-PKB
(0.8 mg), either empty pGW1 () or pGW1-E4-ORF1 (þ ) (20 ng), and either empty pGW1 () or pGW1-HA-Dlg1-I3 (right: 11 ng, 110 ng, 1.1mg,
or 2.2 mg; left: 0.5mg). Cells were serum starved, and equal amounts of cell extracts were blotted with antibody to (P)Thr308 PKB or HA.
(D) Other PDZ proteins fail to augment E4-ORF1-induced PKB activation in Dlg1gt/gt MEF. The latter cells on 6-cm dishes were lipofected with
either empty pGW1 () or pGW1-HA-PKB (þ ) (0.4mg), either empty pCMVBamNeo () or pCMVBamNeo-E4-ORF1 (þ ) (0.1 mg), and either
empty peYFP () or peYFP-Dlg1-I3 (0.3mg), -Dlg1-I2 (0.3mg), -MUPP1 (0.3mg), -MAGI-1c (0.3mg), or -ZO-2 (0.1mg), or peGFP-SAP102 (0.3 mg).
Cells were serum starved, and equal amounts of cell extracts were blotted with antibody to (P)Thr308 PKB, HA, or GFP. (E) Dlg1-I3 likewise
enhances PKB activation induced by E4-ORF1 encoded by other human adenoviruses. Dlg1gt/gt MEF on 6-cm dishes were lipofected with pGW1-
HA-PKB (0.4mg), either empty pCMVBamNeo () or the indicated pCMVBamNeo-E4-ORF1 plasmid (Ad9, 0.1mg; Ad3, 0.6mg; Ad5, 0.6 mg), and
either empty peGFP () or peGFP-Dlg1-I3 (þ ) (0.4mg). Cells were serum starved, and equal amounts of cell extracts were blotted with
antibody to (P)Thr308 PKB, HA, or SAP97. (F) Dlg1-I3 fails to augment PKB activation by other cellular and viral oncoproteins in Dlg1gt/gt MEF.
The latter cells on 6-cm dishes were lipofected with pGW1-HA-PKB (0.4mg), either empty pGW1 () or pCMVBamNeo-E4-ORF1 (0.1 mg), pGW1-
RasV12 (0.2 mg), or pPyMT (0.2mg), and either empty peGFP () or peGFP-Dlg1-I3 (þ ) (0.2mg). Cells were serum starved, and equal amounts
of cell extracts were blotted with antibody to (P)Thr308 PKB, HA, or SAP97.
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I3DGK, which partially accumulated in the nucleus, a prop-
erty that likely explained the modest defect of this mutant in
E4-ORF1-induced membrane translocation (Table I).
More important, the majority of Dlg1 proteins that could
support wt levels of E4-ORF1-induced PKB activation were
fully competent for E4-ORF1-induced membrane transloca-
tion (I1I3, DNT, DPDZ3, DSH3, DU3/PDZ3, DPDZ3/SH3,
DNT/SH3, DNT/U3/PDZ3), whereas all Dlg1 proteins having
little or no capacity to support E4-ORF1-induced PKB activa-
tion displayed very weak or no E4-ORF1-induced membrane
translocation (I2, DPDZ2, DPDZ1þ 2, D3PDZ, DU3/SH3,
DU3/PDZ3/SH3, DNT/U3/PDZ3/SH3) (Table I). These find-
ings revealed an intimate connection between E4-ORF1-
induced PI3K activation and Dlg1 membrane translocation,
though some slight deviations from this trend were noted. For
example, DPDZ1 displayed modestly impaired E4-ORF1-
induced PKB activation, yet wt levels of E4-ORF1-induced
membrane translocation, and, conversely, DSH3, DPDZ3/
SH3, and DNT/SH3 exhibited wt levels of E4-ORF1-induced
PKB activation, yet modestly impaired E4-ORF1-induced
membrane translocation (Table I). These observations may
indicate that PDZ1 and SH3 have some specific role in PI3K
activation or Dlg1 membrane translocation, respectively,
induced by E4-ORF1.
Ras mediates Dlg1-dependent PI3K activation induced
by E4-ORF1
The fact that we consistently failed to detect PI3K associated
with either Dlg1 or E4-ORF1 in cells (data not shown) implied
that E4-ORF1 indirectly activates PI3K through a cellular
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Figure 4 The I3, PDZ1þ 2, and U3 or SH3 elements of Dlg1 are required for E4-ORF1-induced PKB activation. (A) Illustration of Dlg1 isoforms
and deletion mutants. Mutants below Dlg1-I3 are derived from this isoform. (B) The PDZ1þ 2 conformational unit is required for Dlg1-I3 to
augment E4-ORF1-induced PKB activation in Dlg1gt/gt MEF. The latter cells on 6-cm dishes were lipofected with pGW1-HA-PKB (0.4mg), either
empty pGW1 () or pGW1-E4-ORF1 (þ ) (20 ng), and either empty peGFP () or the indicated peGFP-Dlg1 plasmid (0.4mg). Cells were serum
starved, and equal amounts of cell extracts were blotted with antibody to (P)Thr308 PKB, HA, or GFP. (C) The PDZ1þ 2 conformational unit is
necessary and sufficient to mediate binding of Dlg1 to E4-ORF1. For the co-precipitation assay (left), 293 Tcells on 6-cm dishes were lipofected
with pGW1-E4-ORF1 (1mg) and either pGW1-Dlg1-I2 or pGW1-Dlg1-I2DPDZ1þ 2 (1mg). Equal amounts of cell extracts were precipitated with
Dlg1 antibody. Recovered proteins (left) and cell extracts (right) were blotted with antibody to SAP97 or E4-ORF1. For the GST pulldown assay
(right), 293 T cells on 6-cm dishes were lipofected with the indicated pGW1-HA-Dlg1-PDZ domain plasmid (1mg). An equal amount of cell
extract was incubated with GST-E4-ORF1 fusion protein (5mg). Recovered proteins (left) and cell extracts (right) were blotted with HA
antibody. (D) Either U3 or SH3 is required for Dlg1 to augment E4-ORF1-induced PKB activation in Dlg1gt/gt MEF. The latter cells on 6-cm dishes
were lipofected with pGW1-HA-PKB (0.4mg), either empty pGW1 () or pGW1-E4-ORF1 (þ ) (20 ng), and either empty peGFP () or the
indicated peGFP-Dlg1 plasmid (left, 0.1mg; right, 0.4mg). Cells were serum starved, and equal amounts of cell extracts were blotted with
antibody to (P)Thr308 PKB, HA, or GFP.
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intermediate, such as receptor or nonreceptor tyrosine kina-
ses, heterotrimeric G-protein-coupled receptors, or mono-
meric G-proteins. Due to additional failures at detecting
associations between PI3K and tyrosine-phosphorylated pro-
teins in E4-ORF1-expressing cells (Supplementary Figure 2A)
and at diminishing E4-ORF1-induced PKB activation with
specific inhibitors of receptor tyrosine kinases (genistein)
or src kinases (PP2) (data not shown), as well as hetero-
trimeric G-proteins (Supplementary Figure 2B), our subse-
quent efforts focused on Ras monomeric G-proteins. We
found that expression of dominant-negative mutant H-Ras-
N17 substantially diminished E4-ORF1-induced PKB activa-
tion in mouse 3T3 cells (Figure 6A), as well as in Dlg1gt/gt
MEF reconstituted with GFP-Dlg1-I3 (Figure 6B). These re-
sults were specific because H-Ras-N17 did not inhibit PKB
activation induced by constitutively activated PI3K (Auger
et al, 2000) (Figure 6A). Moreover, expression of wt H-Ras,
as well as wt N-Ras and K-Ras (data not shown), but not
wt R-Ras, reproducibly augmented E4-ORF1-induced PKB
activation (Figure 6A).
Considering that Ras normally stimulates not only the PI3K
pathway but also the Raf/MEK/ERK pathway, the notion
that Ras mediates E4-ORF1-induced PI3K activation initially
seemed contradictory to the reported absence of activated
ERK1/2 in E4-ORF1-expressing CREF cells (Frese et al, 2003).
In fact, we consistently detected lower levels of activated,
phosphorylated ERK1/2 in E4-ORF1-expressing CREF cells
than in control CREF cells (Figure 6C). Reports showing that
activated PKB can inhibit Raf activation (Zimmermann and
Moelling, 1999), however, provided a plausible explanation
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Figure 5 Binding of E4-ORF1 to Dlg1-I3 promotes their translocation to the plasma membrane. (A) E4-ORF1 fails to sequester endogenous
Dlg1 within detergent-insoluble complexes. Confluent CREF cells stably transfected with empty pBABE (vector) or pBABE-E4-ORF1 (E4-ORF1)
were lysed either in sample buffer to isolate total cell extracts (T) or in RIPA buffer to isolate detergent-soluble (S) and detergent-insoluble (I)
fractions. Equal amounts of cell extracts were blotted with antibody to SAP97, ZO-2, or E4-ORF1. (B) E4-ORF1 promotes endogenous Dlg1 to
accumulate at the plasma membrane. Confluent cells described in (A) were subjected to indirect IF assays with antibody to SAP97 or ZO-2 and
visualized by fluorescence microscopy. Dlg1 and ZO-2 signals are green, whereas DAPI-stained nuclei are red. The top center and right panels
show Dlg1 staining for two independent CREF-E4-ORF1 lines. White arrows denote examples of Dlg1 plasma membrane staining absent in
control CREF cells. (C) Chlorpromazine (cpz) substantially increases Dlg1 plasma membrane staining in E4-ORF1-expressing cells. Confluent
cells described in (A) were untreated or treated with cpz for 30 min and subjected to indirect IF assays with SAP97 antibody. Results represent
the average of two independent experiments, where 4100 cells were analyzed. (D) E4-ORF1/Dlg1-I3 complexes translocate to the plasma
membrane. 293 Tcells cultured on coverslips in 24-well plates were lipofected with the indicated peGFP-Dlg1 isoform (0.5mg) and either empty
pGW1 or pGW1-E4-ORF1 (0.5mg). Cells were subjected to indirect IF assays with E4-ORF1 antibody and visualized by fluorescence microscopy.
(E) E4-ORF1 binding per se triggers Dlg1 translocation to the plasma membrane. 293 T cells cultured on coverslips in 24-well plates were
lipofected with peGFP-Dlg1-I3 (0.5mg) and pGW1-E4-ORF1, -IIIA, or -IIB (0.5 mg). Cells were fixed and visualized by fluorescence microscopy.
The efficiency of wt and mutant E4-ORF1 proteins to promote translocation of cytoplasmic GFP-Dlg1-I3 to the plasma membrane
was determined by quantifying the fraction of GFP-positive cells showing GFP membrane staining. The efficiency of wt E4-ORF1 was
arbitrarily set to 100%, and the efficiency of mutant IIIA or IIB was reported as a percentage of this value. Results represent the average of three
independent experiments, where4100 cells were analyzed. The E4-ORF1 PBM or D2 is specifically disrupted in mutant IIIA or IIB, respectively
(see text).
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for these observations. For example, E4-ORF1 could concei-
vably increase Ras signaling selectively through the PI3K/
PKB pathway and thereby promote PKB-mediated suppres-
sion of Raf. If so, we predicted that treatment with a PI3K
inhibitor to block PKB activation would cause activated
ERK1/2 to accumulate above basal levels in E4-ORF1-expres-
sing cells, but not in control cells. The fact that experiments
with CREF cells (Figure 6C) and MEF (unpublished data)
yielded this exact outcome supported the contention that
Ras mediates Dlg1-dependent PI3K activation induced by
E4-ORF1.
Model
Based on our cumulative results and published findings
on Dlg1, we propose the following model for Dlg1-dependent
PI3K activation by the viral E4-ORF1 oncoprotein (Figure 7).
(1) In the cytoplasm, the PBM of E4-ORF1 mediates an
interaction with Dlg1 PDZ1þ 2, which functions as a mole-
cular switch. With PDZ1þ 2 unoccupied, Dlg1 favors a closed
conformation and localizes in the cytoplasm because steri-
cally hindered SH3, I3, and possibly U3 cannot bind mem-
brane- and cytoskeleton-associated complexes at the plasma
membrane. (2) With PDZ1þ 2 occupied by E4-ORF1, cyto-
plasmic Dlg1 in a closed conformation undergoes a dramatic
structural change to an open conformation, where SH3, I3,
and U3 are exposed and active to engage in protein inter-
actions. (3) By binding to membrane- and cytoskeleton-
associated proteins at the plasma membrane, (4) SH3, I3,
and U3 recruit cytoplasmic E4-ORF1/Dlg1 complexes to the
plasma membrane. (5) E4-ORF1 D2 recruits pp70 into the
heterocomplex. (6) The resulting heterocomplex activates
Ras, which constitutively localizes at the plasma membrane,
by an undetermined E4-ORF1 D2-dependent mechanism that
channels most signaling to the PI3K pathway.
Discussion
Tumor viruses represent proven powerful tools to reveal
mechanisms commonly underlying the development of
human cancers. Given that Dlg1 is targeted not only by
Table I Capacities of wt and mutant Dlg1 proteins to support E4-
ORF1 functions
E4-ORF1 function
Dlg1 proteina Dlg1 translocation to
the plasma membrane
(percentage of cells)b
PI3 K activation
(strength relative
to wt Dlg1-I3)c
Group 1
I2 0.370.6 
I1I3 7573.6 +++
I3 7178.6 +++
DNT 6674.6 +++
DPDZ1 7572.6 ++
DPDZ2 3.372.3 +
DPDZ1+2 0.070.0 
DPDZ3 6973.5 +++
D3PDZ 0.070.0 
DSH3 45711 +++
DGK 4476.7 ++
Group 2
DU3/PDZ3 6372.6 +++
DU3/SH3 0.070.0 
DPDZ3/SH3 3675.1 +++
DU3/PDZ3/SH3 0.070.0 
DNT/SH3 4278.4 +++
DNT/U3/PDZ3 6477.0 +++
DNT/U3/PDZ3/SH3 0.070.0 
aAll mutants below Dlg1-I3 are derived from this isoform.
bAverage percentage of transfected cells (7standard deviation) that
displayed prominent plasma membrane localization in the presence
of wt E4-ORF1. Results represent three independent experiments,
where 4100 cells were analyzed.
cExcept for the mutant DU3/PDZ3/SH3 data, which were not
shown, results summarize data presented in Figures 4B and D.
+++, wt activity; ++ modest defect; +, severe defect; , no
activity.
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Figure 6 PKB activation by E4-ORF1 requires Ras. (A) Dominant-
negative (DN) Ras-N17 inhibits E4-ORF1-induced PI3K activation.
NIH 3T3 cells on 6-cm dishes were lipofected with pGW1-HA-PKB
(0.5mg) and the indicated combinations of pGW1-E4-ORF1 (25 ng),
pGW1-H-Ras-wt (100 ng), pGW1-H-Ras-N17 (500 ng), pGW1-R-Ras-
wt (100 ng), and pCDNA3-myr-p110a coding for constitutively acti-
vated PI3K (PI3K*) (25 ng). Cells were serum starved, and equal
amounts of cell extracts were blotted with antibody to (P)Thr308
PKB, HA, or H-Ras. (B) Ras-N17 also inhibits Dlg1-dependent E4-
ORF1-induced PKB activation in Dlg1gt/gt MEF. The latter cells on
6-cm dishes were lipofected with pGW1-HA-PKB (0.4 mg), empty
pCMVBamNeo () or pCMVBamNeo-E4-ORF1 (þ ) (0.1mg), empty
pGW1 () or pGW1-RasN17 (þ ) (1.0mg), and empty peGFP ()
or peGFP-Dlg1-I3 (þ ) (0.4mg). Cells were serum starved, and an
equal amount of cell extract was blotted with antibody to (P)Thr308
PKB, HA, or SAP97. (C) Treatment with the PI3K inhibitor LY
unmasks ERK activation by E4-ORF1 in CREF cells. Confluent
CREF cells stably transfected with pBABE (vector) or pBABE-E4-
ORF1 (E4-ORF1) were serum starved () and treated with 50mM LY
(þ ) for 1 h. An equal amount of cell extract was blotted with
antibody to (P)Thr202/Tyr204 p42/44 MAPK, p42/44 MAPK,
(P)Thr308 PKB, PKB, or E4-ORF1.
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human adenovirus E4-ORF1 but also by HTLV-1 Tax and HPV
E6, deciphering functional consequences for the interaction
between Dlg1 and E4-ORF1 may yield valuable insights into
molecular events promoting adult T-cell leukemia, cervical
carcinoma, and other cancers in people. Significantly, we
showed here that binding of E4-ORF1 to Dlg1 specifically
promotes oncogenic PI3K activation through a Ras-dependent
mechanism. These findings identified the first known
function for endogenous Dlg1 in virus-mediated cellular trans-
formation. The absolute requirement for Dlg1 in E4-ORF1-
induced PI3K activation further revealed a surprising proto-
oncogene function for this suspected tumor suppressor gene.
It is important to point out that, though unexpected, our
finding that Dlg1 possesses an oncogenic activity does not
refute a substantial body of evidence supporting its designa-
tion as a candidate tumor suppressor gene. Viral oncoproteins
typically disregulate normal functions of their cellular targets,
so it may be pertinent that Dlg1 was recently reported
to recruit PI3K into a membrane-associated complex with
E-cadherin to promote both adherens junction formation and
terminal differentiation in enterocytes (Laprise et al, 2004).
As this activity is predicted to induce an antiproliferative state
in cells, it may represent a tumor suppressor function for
Dlg1. Therefore, an intriguing possibility is that, whereas
Dlg1 normally functions to promote temporally and spatially
restricted E-cadherin-dependent PI3K activation during adhe-
rens junction formation in cells, Dlg1 modified by E4-ORF1
instead supports constitutive and spatially unrestricted, Ras-
dependent PI3K activation at the plasma membrane. This
model interestingly hints that E4-ORF1 may simultaneously
inactivate a tumor suppressor function and stimulate an
oncogenic function of Dlg1.
We discovered nearly identical requirements for PDZ1þ 2,
U3, SH3, and I3 in both Dlg1 membrane translocation and
PI3K activation induced by E4-ORF1. The fact that Dlg1
translocation to the plasma membrane by definition must
precede PI3K activation would seem to dictate that Dlg1
solely contributes to the latter process by trafficking E4-
ORF1 to the plasma membrane. Our results cannot, however,
rule out the possibility that one or more crucial Dlg1 domains
function directly in both Dlg1 membrane translocation and
PI3K activation induced by E4-ORF1. Consistent with this
idea, despite exhibiting prominent localization at the plasma
membrane, an E4-ORF1 PBM mutant tagged with a farnesyla-
tion signal failed to activate PI3K in cells (unpublished data).
Our findings showed that PDZ1þ 2 of Dlg1 mediates
binding to E4-ORF1 and that this interaction functions as a
molecular switch to trigger the resulting heterocomplex to
translocate to the plasma membrane, possibly by converting
cytoplasmic Dlg1 in an inactive, closed conformation to an
active, open conformation, where I3, U3, and SH3 can bind
membrane-associated proteins (Figure 7). Supporting this
model, localization of Dlg1 to the plasma membrane in
both epithelial cells and neurons depends in part on I3
(Hanada et al, 2003; Rumbaugh et al, 2003), which binds
ERM family proteins that connect membrane-associated pro-
tein complexes to the cytoskeleton. Furthermore, U3 is repor-
ted to recruit Dlg1 into caveolae through an interaction with
Caveolin-3 (Folco et al, 2004), and SH3 binds CASK (Nix et al,
2000) to form a membrane-associated complex. In addition
Figure 7 Model for Dlg1-dependent PI3K activation by the adenovirus E4-ORF1 oncoprotein. See text for details.
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to their roles in organizing cell–cell membrane junctions,
domains equivalent to Dlg1 PDZ2, SH3, and I3 in Drosophila
Dlg are also essential for its tumor suppressor function
(Hough et al, 1997). This observation suggests that these
domains of Dlg1 may dually regulate its oncogenic and tumor
suppressor activities.
The fact that viral oncoproteins often mimic the cyto-
plasmic domain of activated growth factor receptors may
provide insights into the mechanism whereby E4-ORF1
stimulates Dlg1-dependent Ras activation. Such activated
cytoplasmic domains bind the Grb2 and Shc adaptor proteins,
which, in turn, recruit the Sos guanine nucleotide exchange
factor to the plasma membrane to stimulate Ras activity
(Hancock, 2003). Future studies will investigate whether
these factors also participate in Ras activation induced by
E4-ORF1.
It is unclear whether, like E4-ORF1, high-risk HPV E6 and
HTLV-1 Tax also activate the oncogenic function of Dlg1.
Nonetheless, these viral oncoproteins similarly bind to Dlg1
PDZ1þ 2 (Kiyono et al, 1997; Suzuki et al, 1999), and our
preliminary data suggest that they also promote GFP-Dlg1-I3
translocation to the plasma membrane. Also relevant is a
report of PI3K pathway activation in HTLV-1 Tax-transformed
cells (Liu et al, 2001). In overexpression assays, high-risk
HPV E6 promotes degradation of Dlg1 (Gardiol et al, 1999),
and substantially reduced Dlg1 levels are detected in late-
stage invasive HPV-positive cervical carcinomas (Watson
et al, 2002), consistent with the notion that HPV E6 inacti-
vates Dlg1 in these contexts. Nevertheless, reduced levels of
Dlg1 are found neither in HPV-positive premalignant cervical
lesions (Watson et al, 2002) nor in HPV-infected keratinocytes
(Lee and Laimins, 2004), revealing that HPV E6 has differ-
ential effects on Dlg1 at early versus late stages of cancer
progression. Thus, an intriguing possibility is that HTLV-1 Tax
and HPV E6 likewise activate the Dlg1 oncogenic function to
provoke disregulated plasma membrane signaling and there-
by drive early stages of cancer development.
Materials and methods
Plasmids
pGW1, pCMVBam3-Neo, pBABE encoding wt or mutant E4-ORF1
cDNAs, as well as pGW1-HA-PKB, were previously described
(Weiss et al, 1997; Weiss and Javier, 1997; Frese et al, 2003).
Untagged and HA epitope-tagged wt and mutant Dlg1 cDNAs,
derived from SAP97 cDNAs in pRK174-SAP97-I3 (Muller et al, 1995)
and pGW1-SAP97-I2 (Kim and Sheng, 1996), were inserted into
pGW1, peGFP-C3, or peYFP-C1. The mouse Dlg1 shRNA oligo-
nucleotide (AGGTCCTAAAGGTCTTGGG) was inserted into the
pSUPER-retro plasmid (Oligoengine, Seattle). MUPP1, MAGI-1c,
and ZO-2 cDNAs were inserted into peYFP-C1. H-Ras and R-Ras
cDNAs, generated by PCR amplification from plasmids kindly
supplied by Julian Downward and Andrew Chan, were introduced
into pGW1. Plasmids were also kindly provided by Silvio Gutkind
(pCEFL-m2, pCDNA3-CD8bARKCT), Michael Schneider (pSV-Sport-
RasN17), Tom Roberts (pCDNA3-myr-p110a), Robert Kamen
(pPyMT1), and Nathalie Sans (peGFP-SAP102).
Cells
Cells were maintained in culture medium (Dulbecco’s modified
medium supplemented with gentamicin and 6% or 10% fetal
bovine serum), which was also supplemented with 20 or 5 mg/ml of
puromycin (Sigma) for cells stably transfected with E4-ORF1, PyMT,
or Dlg1 shRNA. MUPP1, MAGI-1, and Dlg1 mutant MEF were
isolated from 13-day embryos of mice missing the Mpdz (MUPP1)
gene (Bell et al, 1995) or having the MAGI-1 gene (in preparation) or
the Dlg1 gene specifically disrupted (Caruana and Bernstein, 2001),
respectively.
Transfections and treatments
Transfections were performed using TransIT-LT1 (Mirus) or
Lipofectamine (Invitrogen Life). Transient experimental analyses
were routinely conducted 48 h post-transfection. In some experi-
ments, cells were serum starved for 16–24 h, during which time
they either remained untreated or were treated with 20 ng/ml
of PDGF-BB (Invitrogen Life), 10 or 50mM LY294002 (LY) (Cell
Signaling Technologies), 100 mM carbachol (Sigma), 50 ng/ml
pertussis toxin (PTx) (Sigma), 10mg/ml chlorpromazine (cpz), or
DMSO vehicle as a control.
Antibodies
Rabbit antisera to MUPP1, MAGI-1, ZO-2, SAP97, and E4-ORF1
were described (Javier, 1994; Lee et al, 1997; Glaunsinger et al,
2000; Glaunsinger et al, 2001). Other antibodies were purchased
from Cell Signaling Technologies (Akt, phospho-Akt(Ser473),
phospho-Akt(Thr308), p42/44 MAPK, phospho-p42/44 MAPK
(Thr202/Tyr204)), Santa Cruz Biotechnologies (phospho-tyrosine
PY20), BD Biosciences (H-Ras, Dlg1, GFP), Upstate Biotech (p85
PI3K), Covance (HA 16B12), Southern Biotechnology Associates
Inc. (horseradish peroxidase-conjugated goat anti-rabbit and anti-
mouse IgG), and Molecular Probes (goat anti-rabbit IgG conjugated
to either AlexaFluor 594 or AlexaFluor 488).
Extracts, immunoprecipitations, immunoblots,
and pulldowns
Cell extracts were prepared in RIPA buffer supplemented with
protease and phosphatase inhibitors as described (Lee et al,
1997). For certain experiments, cell extracts in RIPA buffer were
fractionated by centrifugation (10 000 g, 5 min at 41C) into
detergent-soluble supernatants and detergent-insoluble pellets,
and the latter fractions were resuspended in a volume of sample
buffer equal to that of the detergent-soluble supernatant. Equal
volumes of each fraction were analyzed. GST pulldown, immuno-
precipitation, and immunoblot analyses were carried out as
described previously (Weiss et al, 1996).
Soft agar assays
Soft agar assays were conducted as described previously (Javier,
1994) and were photographed with an Olympus DP11 microscope
digital camera mounted on an Olympus CK40 inverted microscope.
Microscopy
Indirect IF assays were performed as described previously (Frese
et al, 2003). Cells were visualized with a Zeiss Axioplan 2
epifluorescence microscope and photographed with a CoolSnap
HQ CCD camera (Photometrics).
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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